Summary of Study ST000584

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000427. The data can be accessed directly via it's Project DOI: 10.21228/M8VK5D This work is supported by NIH grant, U2C- DK119886.


This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files
Study IDST000584
Study TitleFasting wildtype, tfeb -/- knockout, and lmna -/- knockout metabolite profiling of adult zebrafish
Study SummaryInhibition of mechanistic target of rapamycin (mTOR) activity exerts cardioprotective functions. We propose to assess the metabolite profile in zebrafish cardiomyopathy models to test the cardioprotective role of mTOR-TFEB-autophagy and mTOR-lmna- autophagy signaling in heart, liver, muscle, brain, and kidney tissue. In addition mTOR signaling among zebrafish 2 hour post feeding, 24 hour post feeding, and 48 hour post feeding will be profiled. These studes will be used as a baseline and for protocol development before we assess changes in DOX-induced cardiomyopathy.
Mayo Clinic
Last NameXu
First NameXiaolei
Address200 First Street SW, Rochester, MN 55905
Submit Date2017-03-10
Analysis Type DetailLC-MS
Release Date2019-05-15
Release Version1
Xiaolei Xu Xiaolei Xu application/zip

Select appropriate tab below to view additional metadata details:


Project ID:PR000427
Project DOI:doi: 10.21228/M8VK5D
Project Title:Mayo Metabolomics Pilot and Feasibility Award: Deciphering cardioprotective effects of mTOR inhibition via metabolite profiling
Project Summary:Cardiomyopathy is the most common cause for sudden death and heart failure with tremendous public health burden in the U.S. Accumulating evidence from both animal models and clinical studies in human transplant patients suggests that partial inhibition of mechanistic Taget of Rapamycin (mTOR) signaling is a viable avenue for therapeutic intervention. Specifically, we recently showed both compound (rapamycin) treatment and genetic manipulation using a mechanistic Target of Rapamycin (mTOR) haploinsufficient (mTOR+/-) mutant confers cardiac protection against cardiomyopathies of two different etiologies in zebrafish. Mechanistically, antihypertrophy, anti-apoptosis and proautophagy of mTOR inhibition play important roles in this cardioprotection process. Our central hypothesis is that this mTOR inhibition-mediated cardioprotection is conferred by transcription factor EB (TFEB)-regulated autophagy activation. To test this hypothesis, we propose to pursue a systematic metabolite profiling analysis in the heart upon DOX stress under fine-tuned mTOR inhibition. We expect to define metabolite signatures in different types of cardiomyopathy, metabolite signature for the cardioprotective effects of mTOR inhibition, as well as metabolite signatures for TFEB genetic manipulations. These data will be compared with transcriptome studies to prove functions of TFEB signaling in cardioprotective effects of mTOR inhibition, which shall provide a solid foundation for renewing our current RO1 grant aiming to develop mTOR-based therapy for heart failure.
Institute:Mayo Clinic
Last Name:Xu
First Name:Xiaolei
Address:200 First Street SW, Rochester, MN 55905